Industry layoffs surged last year, claiming about 14,000 jobs across biopharma. While many hoped 2024 would be a turning point, workforce cuts have continued and the worst might not be over, according to Arda Ural, EY Americas industry markets leader, health sciences and wellness.
Bristol Myers Squibb recently announced plans to shed 2,200 jobs by the end of next year, including 860 positions in New Jersey. Bayer slashed its workforce by 1,500 and may jettison more as part of a restructuring effort. Other companies such as Takeda Pharmaceuticals, Bolt Biotherapeutics and Novartis have also pulled out the ax in recent months.
https://www.pharmavoice.com/news/big-pharma-layoffs-patent-cliffs-bms-takeda/718333/